Q1 2025 13F Holders as of 3/31/2025
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
99.6M
-
Number of holders
-
576
-
Total 13F shares, excl. options
-
95.4M
-
Shares change
-
+645K
-
Total reported value, excl. options
-
$10.6B
-
Value change
-
+$6.53M
-
Put/Call ratio
-
0.68
-
Number of buys
-
250
-
Number of sells
-
-331
-
Price
-
$110.60
Significant Holders of NEUROCRINE BIOSCIENCES INC - Common Stock (NBIX) as of Q1 2025
678 filings reported holding NBIX - NEUROCRINE BIOSCIENCES INC - Common Stock as of Q1 2025.
NEUROCRINE BIOSCIENCES INC - Common Stock (NBIX) has 576 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 95.4M shares
of 99.6M outstanding shares and own 95.8% of the company stock.
Largest 10 shareholders include BlackRock, Inc. (14.7M shares), VANGUARD GROUP INC (9.94M shares), Dodge & Cox (5.53M shares), STATE STREET CORP (4.86M shares), JPMORGAN CHASE & CO (2.67M shares), RENAISSANCE TECHNOLOGIES LLC (2.5M shares), WELLINGTON MANAGEMENT GROUP LLP (2.1M shares), GEODE CAPITAL MANAGEMENT, LLC (1.97M shares), Bellevue Group AG (1.82M shares), and PRICE T ROWE ASSOCIATES INC /MD/ (1.54M shares).
This table shows the top 576 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.